Abstract
Multiple myeloma is a plasma cell malignancy almost always preceded by precursor conditions, but low tumor burden of these early stages has hindered the study of their molecular programs through bulk sequencing technologies. Here, we generated and analyzed single cell RNA-sequencing of plasma cells from 26 patients at varying disease stages and 9 healthy donors. In silico dissection and comparison of normal and transformed plasma cells from the same bone marrow biopsy enabled discovery of novel, patient-specific transcriptional changes. Using Bayesian Non-Negative Matrix Factorization, we discovered 15 gene expression signatures which represent transcriptional modules relevant to myeloma biology, and identified a signature that is uniformly lost in neoplastic cells across disease stages. Finally, we demonstrated that tumors contain heterogeneous subpopulations expressing distinct transcriptional patterns. Our findings characterize transcriptomic alterations present at the earliest stages of myeloma, paving the way for exploration of personalized treatment approaches prior to malignant disease.
Competing Interest Statement
F.A. is an inventor on a patent application related to SignatureAnalyzer-GPU; G.G. receives research funds from IBM & Pharmacyclics, and is a founder, consultant, and has privately held equity in Scorpion Therapeutics; G.G is also an inventor on patent applications filed by the Broad Institute related to MSMuTect, MSMutSig, POLYSOLVER, SignatureAnalyzer-GPU, and MSIDetect; I.M.G. is a Consultant for AbbVie, Adaptive, Bristol Myers Squibb, Celgene Corporation, Cellectar, CohBar, Curio Science, Dava Oncology, Genentech, Huron Consulting, Karyopharm, Magenta Therapeutics, Menarini Silicon Biosystems, Oncopeptides, Pure Tech Health, Sognef, Takeda, and The Binding Site; an Advisor for Mind Wrap Medical, LLC; and an Advisor and Consultant for Amgen, Aptitude Health, GlaxoSmithKline, GNS Healthcare, Janssen, Pfizer, and Sanofi. I.M.G.'s spouse, William Savage MD, PhD, is CMO and equity holder of Disc Medicine (Private company, not publicly traded); N.J.H. is a consultant for Constellation Pharmaceuticals; D.S. is a consultant for ASAPP, has privately held equity in Curai and ASAPP, and receives research funds from Takeda and IBM; O.Z. is an employee at Constellation Pharmaceuticals.
Funding Statement
R.B. and D.S were supported by an ASPIRE award from The Mark Foundation for Cancer Research. G.G. is partially supported by the Paul C. Zamecnik Chair in Oncology at the Massachusetts General Hospital Cancer Center. This study was partially funded by the Multiple Myeloma Research Foundation (MMRF), Stand Up to Cancer (SU2C), and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
These studies were approved by the Dana-Farber Cancer Institute IRB. Informed consent was obtained from all patients and healthy volunteers in accordance with the Declaration of Helsinki protocol (fifth revision from 2000 with Clarifications of Articles 29, 30 (20022004), and the most recent iteration from 2013). MGUS and SMM patient samples were collected for a clinical trial, clinicaltrial.gov identifier NCT02269592.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# These authors jointly supervised this work
Data Availability
All data analyzed in the present study will become publicly available when the study is published in a peer-reviewed journal, and are currently available upon reasonable request to the authors.
